Background: The molecular mechanism by which ␣-conotoxin RegIIA inhibits ␣3␤4, ␣3␤2, and ␣7 nAChRs is unknown. Results: Alanine scanning mutagenesis and molecular dynamic simulations of RegIIA revealed Asn 11 and Asn 12 confer improved selectivity at ␣3␤4 nAChR. Conclusion: We synthesized the [N11A,N12A]RegIIA analog that selectively inhibits ␣3␤4. Significance: These findings could be used to develop ␣3␤4-selective drugs to treat lung cancer.
Nicotinic acetylcholine receptors (nAChR) 4 are ligand-gated ion channels expressed in the central nervous system (CNS) and peripheral nervous system (1) . They are pentameric receptors composed of a combination of ␣ subunits (␣2-10) and ␤ subunits (␤2-4). Heteromeric (for example, ␣3␤2 and ␣4␤2) and homomeric isoforms (only ␣7 and ␣9 subunits) of nAChRs exhibit diverse structural and functional heterogeneity (2) . Their physiological role in modulating pre-and post-synaptic transmission in the CNS, and visceral and somatic sensory transmission in the peripheral nervous system are well understood (3, 4) .
nAChRs have been implicated in the pathophysiology of a number of health conditions, including Alzheimer disease, schizophrenia, tobacco addiction, and lung cancer (5) . Our understanding of isoform distribution and neurophysiological roles of individual receptor subtypes in these conditions is limited by a lack of adequate isoform-specific probes (6) .
An initial report suggesting that nAChRs may regulate cancer cell growth (7) was followed by a number of studies investigating the role of nAChRs in cancer development and progression (reviewed in Ref. 8) . Two studies identified tobacco-specific nitrosamines as potent nAChR agonists and inhibitors of cancer cell apoptosis (9) . In addition, genome-wide studies identified associations between lung cancer and several single nucleotide polymorphisms within the gene cluster encoding the ␣3, ␣5, and ␤4 nAChR subunits (10) . Additionally, activation of the ␣3␤4 nAChR, a predominant subtype expressed in sympathetic and parasympathetic neurons of mammalian autonomic ganglia (11) (12) (13) , is known to be associated with nicotine addiction and drug abuse (14, 15) . However, our understanding of the physiological relationship is limited.
Conotoxins are bioactive peptides isolated from the venom of cone snails of the genus Conus (16) . ␣-Conotoxins are a specific class of short, disulfide-constrained peptides with a conserved Cys-framework, CCX n CX m C. X n and X m represent the number of amino acids and are used to subclassify peptides such as ␣4/3, ␣4/4, and ␣4/7, which specifically target various nAChR isoforms (17) . Thus they represent excellent molecular probes to elucidate the physiological roles of nAChR subtypes in normal and disease states (18) . The structural and functional properties of a number of ␣-conotoxins have been characterized (16 -19) . Although ␣-conotoxins such as ImII and RgIA exhibit selective inhibitory activity at ␣7 (20) and ␣9␣10 (21) nAChR subtypes, respectively, most known ␣-conotoxins target multiple nAChR subtypes (16, 17) . ␣-Conotoxin AuIB is the only known peptide that selectively targets the ␣3␤4 nAChR subtype albeit with low potency (IC 50 ϭ 2.5 M) (22, 23) .
Mutagenesis experiments have become an important tool to improve selectivity and potency of receptor inhibitors (see for example, Ref. 24 ). Previously we reported the discovery and isolation from Conus regius venom of the ␣4/7-conotoxin RegIIA (25) . RegIIA potently inhibits ACh-evoked currents of ␣3␤4, ␣3␤2, and ␣7 nAChR isoforms. Given the pathophysiological association of the ␣3␤4 nAChR subtype with various disorders such as lung cancer and nicotine addiction, we have now employed mutagenesis with the aim of improving the selectivity profile of RegIIA. Using alanine scanning mutagenesis and modeling studies, we also identified critical ␣-conotoxin RegIIA residues that interact with ␣3␤2, ␣3␤4, and ␣7 nAChR ACh-binding sites.
EXPERIMENTAL PROCEDURES
Peptide Synthesis-All of the peptide analogs were assembled on rink amide methylbenzhydrylamine resin (Novabiochem; 0.7 mmol g Ϫ1 ) using o-benzotriazole-N,N,NЈ,NЈ-tetramethyluronium hexafluorophosphate (HBTU)-mediated manual solidphase peptide synthesis, with an in situ neutralization procedure for N-(9-fluorenyl)methoxycarbonyl (Fmoc) chemistry. Each cycle consisted of Fmoc deprotection with 20% piperidine in dimethylformamide, followed by Fmoc amino acid coupling using HBTU and N,N-diisopropylethylamine in dimethylformamide. A 2-fold excess of Fmoc amino acids was used in the coupling reactions. All peptides were synthesized in globular conformation (I-III and II-IV disulfide connectivity) through incorporation of Fmoc-Cys acetamidomethyl (Acm)-OH at positions 2 and 8 of the amino acid sequence (I-III disulfide bond). The efficiency of the coupling reactions were checked using the Kaiser Ninhydrin test.
Peptides were cleaved from the dried resin (0.4 g) by treatment with 100 ml of TFA, triisopropylsilane, and water as scavengers (95:2.5:2.5, TFA:triisopropylsilane:water, v/v/v). The reaction was allowed to proceed at room temperature (20 -23°C) for 2.5 h. The TFA was then evaporated, and the peptide was precipitated with ice-cold ether, filtered, dissolved in 50% buffer A/B (buffer A: H 2 O, 0.05% TFA; buffer B: 90% CH 3 CN, 10% H 2 O, 0.045% TFA) and lyophilized. Crude peptides were purified by reversed phase-high performance liquid chromatography (RP-HPLC) on a Phenomenex C18 column using a gradient of 0 -80% buffer B for 80 min and the elutant was monitored at 215/280 nm. Unless otherwise stated, the same conditions were used in subsequent purification steps. Electrospray-mass spectroscopy (ESI-MS) confirmed the molecular mass of the fractions collected.
Fractions displaying the correct molecular mass for linear peptide were pooled and lyophilized for oxidation. Linear peptides were oxidized in two steps. First, they were dissolved in 0.1 M NH 4 HCO 3 (pH 8.2) at a concentration of 0.3 mg/ml. Stirring overnight at room temperature formed the II-IV disulfide bond. The acetamidomethyl (Acm) protecting groups were stable under these conditions. Second, iodine (0.01-0.1 M) was added for 5 min at 37°C, and excess iodine was destroyed by adding sodium ascorbate. This formed the I-III disulfide bond. The oxidized peptides were purified by RP-HPLC using a gradient of 0 -80% buffer B over 160 min. Analytical RP-HPLC and ESI-MS confirmed the purity and molecular mass of the synthesized peptides.
NMR Spectroscopy-Nuclear magnetic resonance (NMR) data for all peptides were recorded on Bruker Avance 500-and 600-MHz spectrometers, with samples dissolved in 90% H 2 O, 10% D 2 O. Two-dimensional NMR experiments included TOCSY (total correlation spectroscopy) and NOESY (nuclear Overhauser effect spectroscopy) recorded at 280 K. Spectra were analyzed using Topspin 1.3 (Bruker) and Sparky software. Unless specified, spectra were recorded at pH 3.5.
Two-electrode Voltage Clamp Electrophysiological Recordings of nAChRs Expressed in Xenopus Oocytes-Stage V-VI oocytes were harvested from mature female Xenopus laevis anesthetized with 0.1% tricaine, following protocols approved by the RMIT Animal Ethics Committee. RNA and Xenopus oocytes were prepared, then nAChR subtypes were expressed in oocytes as described previously (26) . Briefly, cDNAs encoding the rat ␣3, ␤2, and ␤4 subunits, and human ␣7 subunit were subcloned into oocyte expression vector pT7TS and the ␣6/␣3 chimera plasmid was kindly provided by Dr. Michael McIntosh (University of Utah). mRNA corresponding to each subunit was prepared using the mMESSAGE mMACHINE Kit (Ambion, Invitrogen). Oocytes were injected with 5 ng of cRNA for each subtype in a 1:1 ratio. However, for the expression of ␣6/␣3 receptors, 15-20 ng of cRNA for each subunit was injected. The injected oocytes were then incubated for 2-5 days at 18°C in ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4) supplemented with 50 mg/liter of gentamicin and 100 g/units/ml of penicillin-streptomycin, before recording. Membrane currents from Xenopus oocytes were recorded at room temperature (20 -23°C), using a bath solution of ND96 as described above. A two-electrode voltage clamp (virtual ground circuit) with either a GeneClamp 500B amplifier (Molecular Devices, Sunnyvale, CA) or an automated work station with eight channels in parallel, including drug delivery and online analysis (OpusXpress TM 6000A, Axon Instruments Inc.) was used.
All recordings were made using voltage recording and current-injecting electrodes were pulled from borosilicate glass (GC150T-7.5, Harvard Apparatus Ltd., Holliston, MA) and had resistances of 0.3-1.5 M⍀ when filled with 3 M KCl. Oocytes were voltage clamped at a holding potential of Ϫ80 mV. During recordings, oocytes were perfused continuously at a rate of 2 ml/min, with ACh (200 M for ␣7 and 50 M for all other nAChR subtypes) applied for 2 s at 2 ml/min. A 180-to 240-s interval washout period was used between every ACh application. The inhibitory effect of each peptide at the respective concentration represents the ratio of ACh-evoked peak amplitude evoked before and following 300-s incubation with peptide. Data were filtered at 10 Hz and sampled at 500 Hz (27) .
Data Analysis-Concentration-response curves for antagonists were fitted by unweighted nonlinear regression to the logistic equation,
where E x is the response, X is the antagonist concentration, E max is the maximal response, n H is the slope factor, and IC 50 is the antagonist concentration giving 50% inhibition of the maximal response. All electrophysiological data were pooled (n ϭ 4 -8 for each data point) and represent arithmetic mean Ϯ S.E. of the fit. Computation was done using GraphPad Prism 6.03 (GraphPad Software, Inc., La Jolla, CA).
Homology Modeling-Homology models of the extracellular ligand-binding domain of rat (␣3) 2 (␤2) 3 and (␣3) 2 (␤4) 3 nAChRs bound to RegIIA or [N11A,N12A]RegIIA were constructed using the crystallographic coordinates of Aplysia californica acetylcholine-binding protein, co-crystallized with the double mutant ␣-conotoxin PnIA[A10L,D14K] (Protein Data Bank accession code 2BR8) (28) as a template. RegIIA and double mutant peptides were modeled bound to the ␣(ϩ)␤(Ϫ) receptor binding sites using the geometry of the PnIA mutant in the acetylcholine-binding protein crystal structure as a template. This provided a suitable 4/7 ␣-conotoxin-bound conformation of the receptor for subsequent molecular dynamics (MD) simulations and analyses. Rat ␣3, ␤2, and ␤4 sequences were obtained from the Swiss-Prot database (codes P04757, P12390, and P12392, respectively), and aligned with the template sequence using the ClustalW server. BLOSUM was used as the scoring matrix. Using the multiple alignment as input, 10 models each of the RegIIA-␣3␤2, RegIIA-␣3␤4, [N11A,N12A]RegIIA-␣3␤2, and [N11A,N12A]RegIIA-␣3␤4 complexes were generated using Modeler9v6 (29) . The top ranking models were selected and validated using PROCHECK (30) . MD simulations were then done on the top model of each of the four receptor complexes. The overall fold of each homology model complex is qualitatively similar.
MD Simulations-Each of the four receptor complexes was put in a separate cubic simulation box, with an edge length of 100 ϫ 100 ϫ 100 Å, and solvated with 27,229 (for ␣3␤2) or 27,194 (␣3␤4) TIP3P water molecules. To neutralize charge and maintain an ionic concentration of ϳ150 mM, 115 (for ␣3␤2) or 88 (␣3␤4) Na ϩ and 70 Cl Ϫ ions were added to the solvent. All simulations were performed using GROMACS version 4.5.5 (31, 32) , with CHARMM27 force-field version 2.0 (with cmap) (33) .
Before undergoing MD simulations, the complexes were energy minimized using the steepest descent algorithm and an energy gradient convergence criterion of 0.01 kcal/mol/Å. All MD simulations were performed using a constant particle number, pressure, and temperature ensemble, with temperature maintained at 300 K using the v-rescale temperature coupling algorithm (34) , and pressure maintained at 1 bar using the Parrinello-Rahman pressure coupling algorithm (35) . Time steps of 2 fs were used to integrate all simulations.
Solvent equilibration simulations of 100 ps lengths were performed. In these simulations, the non-hydrogen atoms of the receptor and toxins were positionally restrained so the solvent and ions could undergo motions to reach equilibrium from an initially energetically unfavorable state, without disturbing the protein. Subsequent simulations of all four complexes were then performed with all atoms free of the system to undergo dynamics.
To improve conformational sampling, we performed 10 independent simulations for each complex, using different random seeds to assign initial particle velocities. Each simulation was performed for 20 ns (i.e. 200 ns of trajectory per complex). To reduce bias from initial homology model conformations, all analyses were performed on the final 10 ns of the trajectories.
Unless indicated, all data were taken as an average over the 10 independent simulations. Molecular graphics were produced using VMD version 1.9.2 (36) . All analyses were performed using a combination of VMD, GROMACS analysis software suite, and in-house scripts.
The interatomic contact difference plot (⌬N) was calculated by determining the total number of toxin contacts within 4.5 Å of each receptor residue for wild-type and mutant RegIIA, averaged over 10 independent simulations and both ␣(ϩ)␤(Ϫ) interfaces (20 data points per receptor residue). To obtain ⌬N values, the wild-type contact number was subtracted from that of the double mutant.
RESULTS
Synthesis of RegIIA Analogs-We used an alanine scan mutagenesis approach to elucidate the molecular mechanism underlying inhibition of the ␣3␤4 nAChR subtype by RegIIA. This technique is well established, and in conjunction with atomistic MD simulations, has enabled significant advances in molecular pharmacology (see for example Refs. 37 and 38). ␣-Conotoxin RegIIA belongs to the ␣4/7 subclass having the conserved Cys-framework CCX n CX m C. Due to its I-III and II-IV disulfide connectivity, native RegIIA exhibits a classical helical, globular structure (25) . This globular conformation balances the shape, charge, and polarity of the peptide. As ␣-conotoxins contain four cysteines there are two additional disulfide isomers that can form during oxidative folding or disulfide reshuffling, the ribbon (I-IV and II-III disulfide bonds) or bead (I-II and III-IV disulfide bonds) isomers. Changes in the disulfide connectivity are reflected in the peptide conformation and can have a significant impact on ␣-conotoxin potency and specificity at nAChRs (39, 40) .
We used regioselective disulfide bond formation with Acmprotected cysteine residues incorporated at positions 1 and 3, and a two-step oxidation procedure, to produce the alanine mutant peptides in a globular conformation (I-III and II-IV disulfide bonds). The two-step oxidation process was confirmed by RP-HPLC, ESI-MS (Fig. 1) , and two-dimensional NMR. Fig. 2 show the negative 1 H shift values between amino acid positions 3 and 7 indicating the presence of an ␣-helix secondary structure.
Alanine Mutagenesis Reveals Key Residues for RegIIA-nAChR Activity-To understand the structure-activity relationship of RegIIA at nAChRs, we tested loop 2 alanine analogs of RegIIA (at a concentration of 300 nM) on ␣3␤2, ␣3␤4, and ␣7 nAChR subtypes (Fig. 3A). [H14A]RegIIA showed complete loss of activity at all three nAChR subtypes. All RegIIA analogs, except [P13A]RegIIA, showed significantly reduced or complete loss in activity at the ␣7 nAChR subtype (Fig. 3B ). [N9A]RegIIA was the only analog that showed no activity at the ␣3␤4 and ␣7 nAChR subtype, whereas maintaining inhibition at ␣3␤2 subtype. In contrast, we observed improved selectivity of [N11A]RegIIA and [N12A]RegIIA for ␣3␤4 with significantly reduced (ϳ50%) inhibition of the ␣3␤2 nAChR subtype (Fig. 3 n H ϭ Ϫ1.7), a 7-fold less potency than native RegIIA (Fig. 4) . However, at the ␣3␤2 and ␣7 nAChR subtypes, potency decreased by 1,000-(IC 50 ϭ 9.9 M) and 360-fold (IC 50 ϭ 21.5 M), respectively (Table 1) . This indicates a decrease in selectivity for the ␣3␤2 and ␣7 nAChR subtypes. Furthermore, the RegIIA double mutation led to a significant loss in activity at ␣6-containing receptors (Fig. 5 ). In comparison, wild-type RegIIA potently inhibited ␣6/␣3␤2␤3 and ␣6/␣3␤4␤3 nAChR subtypes, with IC 50 values of 40 and 147 nM, respectively (Fig.  5 ). [N11A,N12A]RegIIA had ϳ36-fold less potency at the ␣6/␣3␤4␤3 nAChR subtype than RegIIA ( Fig. 5 and Table 1 ), and no activity at the ␣6/␣3␤2␤3 nAChR subtype at a concentration of 10 M (Fig. 5 ). Inhibition of ␣3␤4 by 100 nM RegIIA and [N11A,N12A]RegIIA was reduced by greater than 40%, with a 10-fold (30 to 300 M) increase in the ACh concentration (data not shown). This shift in the concentration-response relationship clearly indicates that RegIIA and [N11A,N12A]RegIIA are competitive antagonists of ␣3␤4 nAChRs.
Key Toxin-Receptor Interactions Revealed by Homology Modeling and MD Simulations-To understand the higher selectivity of [N11A,N12A]RegIIA for ␣3␤4 than ␣3␤2, we have used homology models and atomistic MD simulations of wild-type RegIIA and [N11A,N12A]RegIIA bound to either ␣3␤2 or ␣3␤4 (Fig. 6A) . The initial homology models of wild-type RegIIA bound to the two nAChR subtypes suggest that Asn 11 and Asn 12 of RegIIA make contact predominantly with the ␣3(ϩ) face, although Asn 11 also makes contact with ␤2-Arg 81 and Lys 79 (␤4-Arg 79 and Ile 77 ) (Fig. 6B) .
Because the interactions between nAChR and RegIIA-Asn 11 / Asn 12 are similar for both ␣3␤2 and ␣3␤4, it is difficult to rationalize the substantial selectivity change after double mutation by employing "static" homology models alone. We therefore employed MD simulations, which take into account solvent, temperature, and protein dynamics, to compare changes in atomic contacts at the wild-type and mutated receptors. In particular, we examined the effects of the [N11A,N12A] mutation on contacts at sites distant from these positions (including the ␤(Ϫ) face, which differs substantially between ␤2 and ␤4), which may help explain the basis of RegIIA selectivity. Fig. 7 shows the change in number of toxin atoms (y axis) residing within 4.5 Å of the molecular surface of each receptor residue (x axis) at the ␣(ϩ)␤(Ϫ) interfaces ("⌬N profiles"). This is a measure of loss (negative values on the y axis) or gain (positive values) of toxin contacts as a result of the [N11A,N12A] double mutation. The ⌬N profiles for ␣3␤2 and ␣3␤4 reveal that the double mutation generally reduces toxin-receptor contacts at ␣(ϩ) face residues. However, the effect at the ␤(Ϫ) face is mixed, with reduced or increased number of contacts for [N11A,N12A]RegIIA showed no activity at ␣6/␣3␤2␤3 (ࡗ) when tested at a concentration of 10 M. Data represents mean Ϯ S.E., n ϭ 3-6. different residues. As expected, mutation of Asn 11 and Asn 12 leads to decreased contact with receptor residues in the immediate proximity of these (RegIIA) positions. Contact between the Asn 11 position with ␣3-Tyr 196 /␤2-Arg 81 (␤4-Arg 79 ), and the Asn 12 position with ␣3-Cys 192 , are reduced compared with that of wild-type RegIIA (Fig. 6B) .
The [N11A,N12A] mutation also markedly reduces toxinreceptor contacts at regions distant from the mutation sites. Of particular interest and to explain the selectivity of the mutant for ␣3␤4, are receptor residues with substantially fewer toxin contacts for ␣3␤2 than ␣3␤4 nAChR subtypes. Some of the pairwise interactions involving these residues are illustrated in Fig. 6C and are also marked with asterisks in Fig. 7 . The most prominent residues include ␣3-Tyr 92 , Ser 149 , Tyr 189 , Cys 192 , and Tyr 196 at the principal face, and ␤2-Trp 57 (␤4-Trp 55 ) and ␤2-Phe 119 (␤4-Gln 117 ) at the complementary face. These residues may be essential for RegIIA inhibition of ␣3␤2. In particular, the marked loss of contact at ␣3-Cys 192 in both ␣3␤2 and ␣3␤4 nAChR subtypes is consistent with similar observations from previous studies of ␣-conotoxin analogs and modifications. van Lierop et al. (41) showed dicarba modification of the C2-C8 disulfide bond in Vc1.1 resulted in loss of activity at ␣9␣10. Their MD simulations showed reduced contact between the modified toxin and Cys-loop disulfide atoms. Grishin et al. (38) found [F9A]AuIB lost its activity at ␣3␤4 with the MD simulations showing reduced contact between the toxin and Cys-loop sulfur atoms due to this mutation. Our current data supports the crucial role of Cys-loop sulfur atoms in conotoxin inhibition of neuronal nAChRs.
Double mutation also caused a loss of contact between Asn 9 / Pro 6 and ␤2-Trp 57 , whereas slightly increasing the contact between Asn 9 /Pro 6 and the homologous position at ␤4-Trp 59 (Fig. 7) . This, in addition to functional data for [N9A]RegIIA showing complete loss in activity at ␣3␤4 (Fig. 3) , suggests interaction between Asn 9 and/␤4-Trp 59 might be important for inhibition of the ␣3␤4 subtype. This loss of toxin contact at ␣3␤2, but not ␣3␤4, may also contribute to the marked selectivity change of the double mutant [N11A,N12A]RegIIA toward the ␣3␤4 nAChR subtype.
DISCUSSION
Since the discovery, in the worm-hunting cone snail Conus imperialis, of ␣-conotoxin ImI and its action on neuronal nAChRs, numerous ␣-conotoxins have been identified and functionally characterized (16 -19) . A number of peptides have been identified from the venom of C. regius, a Western Atlantic worm-hunting cone snail species. These peptides belong to various superfamilies with eight being part of the A-superfamily that is distinguished by cysteine framework I (42) . The conotoxin composition of C. regius venom is clinically relevant because it contains the ␣-conotoxin RegIe and RegIIA both of which have been identified as potential therapeutics. RgIA (free 
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carboxyl C terminus form of [O6P]RegIe) selectively targets pain transmission by modulation of the ␣9␣10 nAChR subtype and high voltage-activated N-type calcium channel currents, via GABA B receptor activation (43) . ␣-Conotoxin RegIIA potently inhibits activity of the ␣3␤4 nAChR subtype (25) that has been implicated in the pathophysiology of lung cancer.
RegIIA exhibits homology with a number of peptides (Table  2) having a conserved SHPA sequence in loop 1 and a NNP motif in loop 2. The Ser and Pro residues of the SHPA motif are highly conserved in peptides of different subclasses that inhibit various nAChR subtypes ( Table 2 ). Sequence variations in loop 2 contribute to the unique nAChR subtype selectivity of ␣-conotoxins (44) . However, the NNP motif is conserved in peptides such as ␣-conotoxins OmIA, EpI, PnIA, TxIA, and ArIB that specifically inhibit ␣3␤2 and ␣7 nAChR subtypes (16) . This observation is consistent with our finding that alanine mutation of the NNP motif of RegIIA significantly affected inhibition at ␣3␤2 and ␣7 nAChR subtypes (Fig. 3A) . Alanine mutations at other positions provided further information about the structure-function relationship between ␣-conotoxins and neuronal nAChRs. Asparagine (RegIIA position nine) to alanine mutation completely abolished inhibition of the ␣7 and ␣3␤4 nAChRs.
The marked shifts in selectivity observed by the analogs for either ␣3␤2 or ␣3␤4 subtype is intriguing given that both receptors share a common principal subunit face at the presumed conotoxin binding site (Fig. 6A) . Previous x-ray studies of ␣-conotoxin-acetylcholine-binding protein complexes, with support from synthetic analogs, have improved our understanding of ligand-receptor interactions (45) (46) (47) . The extracellular N-terminal domains of the ␤2 and ␤4 nAChR subunits bind ␣-conotoxins and exhibit 70% sequence homology. Recent MD simulation studies also reveal well preserved structural topology of ␣3␤2 and ␣3␤4 nAChRs. However, the ACh-binding pocket interface between the ␣ and ␤ subunits was larger in ␣3␤2 than ␣3␤4 nAChR subtypes (48) . Even though, both Asn 11 and Asn 12 primarily interact with the ␣3(ϩ) interface, this difference could explain the shift in selectivity of [N11A] and [N12A]RegIIA for ␣3␤4 over ␣3␤2.
Our findings are also supported by data from a recent molecular docking study of ␣-conotoxin GIC with human ␣3␤2 and ␣3␤4 nAChR subtypes. The study revealed all three subunits have residues that interact with GIC (␣3 subunit: Tyr 92 , Tyr 150 , Tyr 189 , and Tyr 196 ; ␤2 subunit: Trp 57 , Val 111 , Phe 119 , and Leu 121 ; and ␤4 subunit: Trp 57 , Ile 111 , Leu 119 (Gln 119 in rat ␤4) and Leu 121 ). Interestingly, the ␣3-Tyr 196 and ␤2-Phe 119 residues of the ␣3␤2-GIC model were more closely located than the ␣3-Tyr 196 and ␤4-Leu 119 residues of the ␣3␤4-GIC model (48) . A comprehensive receptor mutagenesis study of the various ␣-conotoxins (MII, GID, and PnIA) that inhibit the ␣3␤2 nAChR subtype indicates that the ␤2 subunit pharmacophore comprising Thr 59 , Glu 61 , Val 111 , Phe 119 , and Leu 121 residues, also has a significant role in ligand binding (49) . It is important to note that, whereas both of the above studies identified similar residues interacting with the conotoxins, increasing literature on the pharmacological difference between rat and human nAChR receptors is emerging (50, 51) . The current study was carried out using rat nAChR subunit clones, however, the activity of RegIIA and [N11A,N12A]RegIIA may differ at human nAChR subtypes.
The selective ␣3␤4 antagonist, AuIB, expanded our knowledge of the distribution and physiological functions of this nAChR subtype in various tissues, including dopaminergic signaling in medial habenula (52) , glutamatergic neurotransmission in cardiac vagal neurons (53) , and keratinocyte chemokinesis (54) . However, the low potency of AuIB at ␣3␤4 and its off-target effect on Ca v 2.2 channel modulation via GABA B receptor activation has hampered its use in in vivo studies. Recent studies in development of selective and potent ␣3␤4 antagonists led to the discovery and synthesis of two novel ␣-conotoxins: TxID, a novel ␣4/6-conotoxin from Conus textile that potently blocks ␣3␤4 (IC 50 ϭ 12.5 nM) (55) and TP-2212-59, a synthetic analog of ␣4/4-conotoxin BuIA (IC 50 ϭ 2.3 nM) (56) . Although both peptides are potent inhibitors of the ␣3␤4 nAChR subtype, TxID also inhibits ␣6/␣3␤4 with only 7.5-fold less potency (IC 50 ϭ 94.1 nM) (55) and the activity of TP-2212-59 at other nAChR subtypes such as ␣6-containing receptors is yet to be tested (56) .
We report the successful synthesis of [N11A,N12A]RegIIA, an ␣3␤4 nAChR subtype-selective antagonist. [N11A,N12A]-RegIIA is ϳ4-fold more potent than AuIB and could be used to decipher the physiological role of ␣3␤4 nAChR in pathological states. MD simulations reveal a direct loss in pairwise contacts between positions 11 and 12 and the principal face of the receptor, including destabilization in other toxin-receptor contacts at the complementary face. This is qualitatively consistent with the 1000-fold decrease in [N11A,N12A]RegIIA inhibition of the ␣3␤2 nAChR subtype. Our homology models and MD simulations also suggest that at the ␤2 subunit, Asn 11 is close to two basic residues (␤2-Arg 81 and Lys 79 ); whereas at the ␤4 subunit, Asn 11 is close to one basic (␤4-Arg 79 ) and one non-polar residue (␤4-Ile 77 ). This has implications for rational toxin modification. Based on the receptor environment surrounding Asn 11 , it is possible that a N11K mutant would enhance selectivity for ␣3␤4, because a Lys at position 11 would introduce electrostatic repulsion with ␤2-Arg 81 and ␤2-Lys 79 . There would likely also be a reduction in affinity at ␣3␤4. However, the repulsion between N11K and ␤4-Arg 79 might be partially offset by favorable contacts between the CH 2 groups of N11K and ␤4-Ile 77 . Further efforts to examine and optimize the selectivity of RegIIA are presently ongoing.
Our study increases understanding of the interactions of RegIIA with various nAChR subtypes. It also identifies key residues such as Asn 9 , Asn 11 , and Asn 12 involved in toxin-receptor interaction. This information will be valuable in the design and development of potent, ␣3␤4-selective drugs to treat lung cancer and nicotine addiction.
